Research Progress on Drug-resistance of Acute Lymphoblastic Leukemia--Review.
10.7534/j.issn.1009-2137.2016.01.050
- Author:
Jing-Jing MA
1
;
Yue CHEN
1
;
Liang YU
2
Author Information
1. Department of Hematology, The First People's Hospital of Huaian, Nanjing Medical University, Huai'an 223300, Jiangsu Province, China.
2. Department of Hematology, The First People's Hospital of Huaian, Nanjing Medical University, Huai'an 223300, Jiangsu Province, China. E-mail: yuliangha@163.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow;
physiology;
Cellular Microenvironment;
Drug Resistance, Neoplasm;
Humans;
Membrane Transport Proteins;
physiology;
MicroRNAs;
genetics;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
drug therapy
- From:
Journal of Experimental Hematology
2016;24(1):261-265
- CountryChina
- Language:Chinese
-
Abstract:
Acute lymphoblastic leukemia (ALL) is a malignant clonal disease, its treatment methods include chemotherapy, hematopoietic stem cell transplantation, immunotherapy and molecular targeted therapy. Clinically, ALL patients need to get complete remission through chemotherapy, and then choose the other treatment according to the patient's condition. But the drug resistance has been a biggest obstacle in treatment of ALL. There are many research reports about drug-resistant of ALL at present. In this review, the classic drug resistance mechanisms, such as membrane transporter, gene modifications and some newly finding mechanisms including such as bone marrow microenvironment and Micro RNA and so on are summarized.
